^
    Back
    Association details:
    Biomarker:FERMT3 overexpression
    Cancer:Glioma
    Drug Class:PD1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Ann Med
    Title:

    Independent prognostic biomarker FERMT3 associated with immune infiltration and immunotherapy response in glioma

    Published date:
    10/05/2023
    Excerpt:
    Further analyses revealed that overexpression of FERMT3 was linked to a better response to anti-PD1 therapy.
    DOI:
    https://doi.org/10.1080/07853890.2023.2264325